Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Myriam Schluep

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Revue Medicale Suisse|June 9, 2012
[Multiple sclerosis: beyong first line therapies]Myriam Schluep, Renaud Du Pasquier
Journal of the Neurological Sciences|July 10, 2013
Assessing risks of multiple sclerosis therapiesValeriy Parfenov, Myriam Schluep, Renaud Du Pasquier
Presse Medicale (Paris, France : 1983)|March 7, 2015
Environmental factors in multiple sclerosisVasiliki Pantazou, Myriam Schluep, Renaud Du Pasquier
The Neurologist|June 16, 2015
Management of Fulminant Multiple Sclerosis With Rituximab: A Case ReportValeriy Parfenov, Renaud Du Pasquier, Myriam Schluep
Neurology|August 28, 2013
Author ResponseRenaud A Du Pasquier, Mathieu Canales, Myriam Schluep
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 1, 2008
Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcomeAxel Petzold, Patrik Michel, Michael Stock, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 16, 2019
Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmaciesAline Bourdin, Myriam Schluep, Olivier Bugnon, et al.
Neurology|March 18, 2016
Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromesMarianna Spatola, Renaud Du Pasquier, Myriam Schluep, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 7, 2017
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidenceFrédéric Bacchetta, Amandine Mathias, Myriam Schluep, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 4, 2012
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjectsSamantha Jilek, Myriam Schluep, Giuseppe Pantaleo, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Revue Medicale Suisse|June 9, 2012
[Multiple sclerosis: beyong first line therapies]Myriam Schluep, Renaud Du Pasquier
Journal of the Neurological Sciences|July 10, 2013
Assessing risks of multiple sclerosis therapiesValeriy Parfenov, Myriam Schluep, Renaud Du Pasquier
Presse Medicale (Paris, France : 1983)|March 7, 2015
Environmental factors in multiple sclerosisVasiliki Pantazou, Myriam Schluep, Renaud Du Pasquier
The Neurologist|June 16, 2015
Management of Fulminant Multiple Sclerosis With Rituximab: A Case ReportValeriy Parfenov, Renaud Du Pasquier, Myriam Schluep
Neurology|August 28, 2013
Author ResponseRenaud A Du Pasquier, Mathieu Canales, Myriam Schluep
Journal of Stroke and Cerebrovascular Diseases : the Official Journal of National Stroke Association|July 1, 2008
Glial and axonal body fluid biomarkers are related to infarct volume, severity, and outcomeAxel Petzold, Patrik Michel, Michael Stock, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|June 16, 2019
Promoting transitions of care, safety, and medication adherence for patients taking fingolimod in community pharmaciesAline Bourdin, Myriam Schluep, Olivier Bugnon, et al.
Neurology|March 18, 2016
Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromesMarianna Spatola, Renaud Du Pasquier, Myriam Schluep, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 7, 2017
Progressive multifocal leukoencephalopathy in two natalizumab-treated stepsisters: An intriguing coincidenceFrédéric Bacchetta, Amandine Mathias, Myriam Schluep, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 4, 2012
MOBP-specific cellular immune responses are weaker than MOG-specific cellular immune responses in patients with multiple sclerosis and healthy subjectsSamantha Jilek, Myriam Schluep, Giuseppe Pantaleo, et al.
Pageof 6